Company: NDRA
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001654954-25-011931
Chunk: 34

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 34
---
 |                                  194,776 |     |     |                                                314,650 |     |     |                                         157,105 |     |     |                                                          148,093 |     |     |                                                    98,026 |     | $ |                                                                            0.03 |     |     | (11.5                     | ) |
| 2023 |      |     |                                               - |     |     |                                        - |     |     |                                                646,787 |     |     |                                         452,050 |     |     |                                                          373,351 |     |     |                                                   266,339 |     | $ |                                                                           15.32 |     |     | (10.1                     | ) |
| 2022 |      |     |                                               - |     |     |                                        - |     |     |                                                636,196 |     |     |                                         443,594 |     |     |                                                          430,872 |     |     |                                                   315,373 |     | $ |                                                                           29.42 |     |     | (13.2                     | ) |

| 26 |

| (1) | Mr. Michelon was our former PEO until August 12, 2024 and for each of the 2023 and 2022 fiscal years. Alexander Tokman is our current PEO starting August 13, 2024.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (2) | This column represents the amount of “compensation actually paid” to our PEO as computed in accordance with Item 402(v) of Regulation S-K. In accordance with the requirements of Item 402(v) of Regulation S-K, the amounts disclosed for compensation actually paid reflect the adjustments listed in the table below made to the total compensation amounts reported in the Summary Compensation Table for our PEO by subtracting the value of equity awards reported in the Summary Compensation Table for the applicable Subject Year and adding (or subtracting, as applicable) the following for the applicable Subject Year: (i) the year-end fair value of any equity awards granted in the Subject Year that are outstanding and unvested as of the end of the Subject Year; (ii) for awards that are granted and vest in the Subject Year, the fair value as of the vesting date; (iii) the amount of change as of the end of the Subject Year (from the end of the prior fiscal year) in the fair value of any